Suppr超能文献

地塞米松预防儿童拔管后喘鸣

Dexamethasone in the prevention of postextubation stridor in children.

作者信息

Tellez D W, Galvis A G, Storgion S A, Amer H N, Hoseyni M, Deakers T W

机构信息

Division of Pediatric Intensive Care, Childrens Hospital Los Angeles, CA 90027.

出版信息

J Pediatr. 1991 Feb;118(2):289-94. doi: 10.1016/s0022-3476(05)80505-0.

Abstract

To assess whether there is any advantage in the use of corticosteroid to prevent postextubation stridor in children, we conducted a prospective, randomized, double-blind trial of dexamethasone versus saline solution. The patients were evaluated and then randomly selected to receive either dexamethasone or saline solution according to a stratification based on risk factors for postextubation stridor: age, duration of intubation, upper airway trauma, circulatory compromise, and tracheitis. Dexamethasone, 0.5 mg/kg, was given every 6 hours for a total of six doses beginning 6 to 12 hours before and continuing after endotracheal extubation in a pediatric intensive care setting. There was no statistical difference in incidence of postextubation stridor in the two groups; 23 of 77 children in the placebo group and 16 of 76 in the dexamethasone group had stridor requiring therapy (p = 0.21). We conclude that the routine use of corticosteroids for the prevention of postextubation stridor during uncomplicated pediatric intensive care airway management is unwarranted.

摘要

为评估使用皮质类固醇预防儿童拔管后喘鸣是否有任何优势,我们进行了一项地塞米松与生理盐水对比的前瞻性、随机、双盲试验。根据拔管后喘鸣的危险因素(年龄、插管时间、上呼吸道创伤、循环功能不全和气管炎)进行分层,对患者进行评估,然后随机选择接受地塞米松或生理盐水。在儿科重症监护环境中,于气管插管前6至12小时开始,每6小时给予地塞米松0.5mg/kg,共六剂,气管插管后继续给药。两组拔管后喘鸣的发生率无统计学差异;安慰剂组77名儿童中有23名、地塞米松组76名中有16名出现需要治疗的喘鸣(p = 0.21)。我们得出结论,在无并发症的儿科重症监护气道管理中,常规使用皮质类固醇预防拔管后喘鸣是不必要的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验